Remaxol® in Malignant Mechanical Jaundice

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

February 3, 2020

Study Completion Date

March 4, 2020

Conditions
Jaundice; Malignant
Interventions
DRUG

Remaxol®

Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle

DRUG

Ringer's Solution

Solution for intravenous infusion, 400 or 800 ml

Trial Locations (18)

Unknown

GBUZ 'Bryansk City Hospital #1', Bryansk

Regional Clinical Hospital of Emergency Care n.a.M.A.Podgorbunsky, Kemerovo

KBUZ 'Regional Clinical Hospital', Krasnoyarsk

OBUZ 'Kursy Regional Clinical Oncology Dispensary' of Kursky Regional Healthcare Department, Kursk

Moscow City Clinical Hospital #1 n.a.N.I.Pirogov, Moscow

Moscow City Clinical Hospital #29 n.a.N.A.Bauman, Moscow

Omsk Regional Clinical Oncology Center, Omsk

"GBUZ Penza Regional Clinical Hospital na N.N.Burdenko", Penza

City Clinical Hospital of Emergency Care, Ryazan

GBUZ 'Leningrad Regional Oncology Center', Saint Petersburg

GBUZ Leningrad Regional Clinical Hospital, Saint Petersburg

Hospital for War Veterans, Saint Petersburg

North-West State Medical University named after I.I. Mechnikov, Saint Petersburg

Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine, Saint Petersburg

"SPb GBUZ City Hospital №26", Saint Petersburg

SPb GBUZ 'City Mariinskaya Hospital', Saint Petersburg

"OGAUZ Tomsk Regional Clinical Hospital", Tomsk

Siberian State Medical University, Tomsk

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT03416062 - Remaxol® in Malignant Mechanical Jaundice | Biotech Hunter | Biotech Hunter